Table 1.
Baseline characteristics of study patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia, according to received intervention*
| Characteristic | PAE (n=48) | TURP (n=51) |
|---|---|---|
| Age (years) | 65.7 (9.3) | 66.1 (9.8) |
| Body mass index† | 26.5 (4.2) | 27.0 (3.9) |
| Charlson comorbidity index | 3.6 (1.6) | 4.3 (2.1) |
| IPSS | 19.38 (6.37) | 17.59 (6.17) |
| Prostate specific antigen concentration (μg/L) | 4.2 (5.4) | 4.5 (5.6) |
| Prostate volume (mL) | ||
| Measured by transabdominal ultrasound | 51.2 (16.5) | 52.1 (18.6) |
| Measured by magnetic resonance imaging | 52.8 (32.0) | 56.5 (31.1) |
| Medical treatment of lower urinary tract symptoms before surgery (No (%) of patients) | ||
| 5α-reductase inhibitors | 0 | 1 (2.0) |
| α1-adrenergic receptor antagonists | 26 (54.2) | 22 (43.1) |
| Combination of both drugs mentioned above | 14 (29.2) | 13 (25.5) |
| Antimuscarinic drugs | 8 (16.7) | 9 (17.6) |
| Total No receiving drug treatment | 41 (85.4) | 44 (86.3) |
| Indwelling urethral catheter at baseline (No (%) of patients) | 9 (18.8) | 12 (24.5) |
Data are mean (standard deviation) unless indicated otherwise. IPSS=international prostate symptoms score; PAE=prostatic artery embolisation; TURP=transurethral resection of the prostate.
*
Baseline symptom scores other than IPSS, micturition parameters, and urodynamic findings are reported in figure 2 and figure 3.
†
Body mass index calculated as weight in kilograms divided by height squared in metres.